Although blockade of the PD-1/PD-L1 axis has emerged as a prominent immunotherapeutic strategy against invasive cancers, its efficacy is often limited by the presence of terminally exhausted CD8+ tumor-infiltrating T cells [26]. The gene discussed is CD8A; the disease is cancer.